Please select the option that best describes you:
Topics:
Genitourinary Cancers • Bladder Cancer • Medical Oncology • Journal Club ft. NEJM publications
Based on NIAGARA data, do you now feel more comfortable offering cisplatin based chemotherapy to patients with impaired renal function?
Do you view creatinine clearance of 40 mL/min as the new cutoff for "cisplatin eligibility"?
Answer from: Medical Oncologist at Community Practice
I agree, apart from the topline positive results in the intent-to-treat population, the preplanned subgroup analysis of lower GFR patients also appears to indicate a benefit, albeit somewhat less strong than traditional criteria. This adds to evidence from the phase 3 randomized VESPER trial of ddMV...
Sign in or Register to read more